4D Lifetec banks CHF 1.9 in series B round
Summary
Zug-based startup 4D Lifetec, focusing on developing and marketing early-stage liquid biopsy cancer diagnostics, raised CHF 1.9 million in the first closing of its Series B round. This extraordinary high mortality rate yet again demonstrates the consequences of the lack of novel, reliable early detection biomarkers and the urgent need to address one of the major threats to the healthcare systems of the modern era.4D Lifetec AG is a pioneering company in non-genomic liquid biopsy cancer diagnostic. This diagnostic information is breakthrough progress to tackle the catastrophic mortality rates of lung cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics.Due to its proprietary transformational DDS biomarker, 4D Lifetest has several possibilities to expand its market activities, become a key element in the diagnostic cascade for other major cancer types and support other liquid biopsy methods by adding high early detection sensitivity. The funds will enable the startup to launch its early lung cancer detection liquid biopsy assay 4D Lifetest Lung Dx in Europe.Arne Faisst, Chief Executive Officer of 4D Lifetec: This first important step in the Series B financing enables us to maintain the high pace of our launch activities in Europe and start our US operations. We are sincerely gratified by the long-term commitment of our existing investors and welcome our new private and strategic investors helping us to prepare the company for its next growth phase.The confidence of 4D Lifetecs investors and the strong interest of established diagnostic and biotech companies in its liquid biopsy-based early cancer detection assay, validate the importance of the sector and the value of the companys portfolio of de-risked assets.